Lexaria Bioscience Corp. (NASDAQ:LEXX) says its Human Pilot Study #7, identified as GLP-1-H26-7, has reached full enrollment and remains on its planned dosing schedule. The study is examining two oral DehydraTECH-semaglutide, or DHT-sema, formulations alongside Novo’s commercially available Wegovy® tablets over a 5-week period.
The company said the final arm was fully enrolled and started dosing in early October. Lexaria expects this group to finish dosing in mid-November, after which laboratory samples will be analysed and reported. The company said it plans to provide another progress update once dosing across the study has been completed.
GLP-1-H26-7 contains three arms designed to assess safety, tolerability and pharmacokinetic properties. The study compares SNAC-inclusive DHT-sema formulations delivered in tablet and capsule formats with commercially available Wegovy® tablets.
Dosing is taking place under fasted pre-dose conditions similar to the administration criteria advised for Novo’s oral semaglutide products. Lexaria said the 5-week duration was selected to allow semaglutide concentrations in the body to reach steady state, described as a point at which drug input is balanced by natural elimination.
The study marks the first time Lexaria is evaluating an oral DHT-sema tablet. Earlier DehydraTECH GLP-1 studies used capsule formulations only. The company said its tablet design attempts to incorporate certain physical characteristics of the SNAC-inclusive tablet delivery approach used by Novo’s Rybelsus® and Wegovy® products.
Both the DHT-sema tablet and capsule test articles contain SNAC. Lexaria said this is the first human evaluation of these formulations over a multi-dose, multi-week period.
For context, Human Pilot Studies #1 and #2, designated GLP-1-H24-1 and GLP-1-H24-2, were conducted in 2024 and 2025. Those studies included SNAC but not tablets, and used single-dose designs that were shorter than the current study.
Lexaria said the study is fully funded through existing corporate resources. The company describes DehydraTECH™ as a patented formulation and processing platform intended for oral drug delivery. Lexaria says the technology has evidenced the ability to increase bio-absorption, reduce side-effects and deliver some drugs more effectively across the blood-brain barrier.
Lexaria operates an in-house research laboratory and says it holds 66 patents granted, with additional patents pending worldwide.
Lexaria’s release states that its forward-looking statements involve risks and uncertainties, including regulatory requirements and approvals, scientific discovery, potential adverse effects associated with products using DehydraTECH, and possible delays or cancellations of planned research and development.
The company also states that there is no assurance that the proposed uses, benefits or advantages of its patented and patent-pending technology will be realised. No statement in the release has been evaluated by the U.S. Food and Drug Administration, and Lexaria-associated products are not intended to diagnose, treat, cure or prevent any disease.
Lexaria Bioscience Corp. announced on October 21, 2026 that full enrollment had been reached and dosing was continuing on schedule in Human Pilot Study #7, GLP-1-H26-7. The study is evaluating two oral DehydraTECH-semaglutide compositions against Novo's® commercially available Wegovy® tablets over a 5-week duration.
Lexaria Bioscience Corp. announced the update on October 21, 2026. The announcement covers the status of Human Pilot Study #7, including its full enrollment and ongoing dosing.
Lexaria Bioscience Corp. said the final study group began dosing in early October and is expected to complete dosing in mid-November. The company said this will be followed by completion of all laboratory sample analyses and reporting.
The study is evaluating two oral DehydraTECH-semaglutide, or DHT-sema, compositions against commercially available Wegovy® tablets. Lexaria said it is assessing safety, tolerability and pharmacokinetic properties.
Lexaria Bioscience Corp. said the study has three separate arms. These compare SNAC-inclusive DHT-sema compositions in tablet and capsule formats with commercially available Wegovy® tablets.
The study is being conducted under fasted pre-dose conditions similar to the advised administration criteria of Novo's oral semaglutide products. The source does not describe any other administration conditions.
Lexaria Bioscience Corp. said the 5-week dosing duration was selected to allow semaglutide concentrations to reach steady state. The company described steady state as an equilibrium in which drug input is balanced by natural bodily elimination.
Lexaria Bioscience Corp. is using an oral tablet DHT-sema composition for the first time, rather than only capsule compositions used in its previous DehydraTECH™ GLP-1 studies. The company said it has attempted to mimic and integrate certain physical properties of the SNAC-inclusive tablet delivery modality used by Novo's Rybelsus® and Wegovy® products.
Both Lexaria Bioscience Corp.'s DHT-sema tablet and capsule test articles are formulated with SNAC. The company said this is the first time these formulations will be evaluated over a multi-dose, multi-week period in humans.
Lexaria Bioscience Corp. said Human Pilot Studies #1 and #2, GLP-1-H24-1 and GLP-1-H24-2, were conducted in 2024 and 2025 and incorporated SNAC but did not use tablets. Those studies used single-dose designs and were therefore much shorter, whereas GLP-1-H26-7 has a 5-week dosing duration.
Lexaria Bioscience Corp. said the study is fully funded from existing corporate resources.
Lexaria Bioscience Corp. describes itself as a global innovator in drug delivery platforms. Its patented DehydraTECH™ formulation and processing platform is designed for oral delivery and, according to the company, has evidenced the ability to increase bio-absorption, reduce side-effects and deliver some drugs more effectively across the blood-brain barrier.
Lexaria Bioscience Corp.'s shares trade on NASDAQ under the ticker symbol LEXX, shown in the source as NASDAQ:LEXX.
Lexaria Bioscience Corp. said the final group is expected to complete dosing in mid-November, followed by laboratory sample analyses and reporting. The company said it will provide a further progress update once all dosing has been completed.
Lexaria Bioscience Corp. said its forward-looking statements involve risks and uncertainties, including market conditions, government regulation and regulatory approvals, scientific discovery, potential adverse effects from products using DehydraTECH technology, and delays or cancellations of planned research and development. The company also said there is no assurance that the postulated uses, benefits or advantages of its patented and patent-pending technology will be realised, and that no statement in the release has been evaluated by the FDA.